Cognitive
Selank
Also known as: TP-7 · tuftsin analogue
Identity and specification
- CAS number
- 129954-34-3
- Molecular formula
- C33H57N11O9
- Molar mass
- 751.88 g/mol
Batch certificates on file
Figures below are copied from independent certificates prepared by ILS Laboratories, San Diego, CA. A figure describes one tested lot and nothing beyond it; the PDF holds the complete report and chromatogram.
Lot SLK08 · Selank 10 mgView certificate (PDF)
- Purity specification
- ≥ 99.0% (HPLC)
- Lot result
- 99.57% — Lot SLK08, assayed 14 Aug 2026Average of all vials sampled in this lot: 99.54%
- Laboratory
- ILS Laboratories, San Diego, CA
- Method
- HPLC, identity by retention-time match to reference standard
- Certificate
- COA-2026-957000
- Labelled content
- 10 mg
- Net peptide content
- 10.45 mg
- Identity (HPLC-RTM)
- Selank — confirmed
- Heavy metals (ICP-MS)
- As, Cd, Cr, Hg, Pb — not detected
- Sterility (PCR)
- No growth
- Endotoxin (USP <85>)
- 0.053 EU/mL
- Fentanyl screen
- Not detected
Selank Mist Applicator 40 mg
- Purity specification
- ≥ 99.0% (HPLC)
- Lot result
- Awaiting lot certificate
Semax + Selank + Pinealon Mist Applicator 60 mg
- Purity specification
- ≥ 99.0% (HPLC)
- Lot result
- Awaiting lot certificate
Published study designs
Study parameters below are reported as published. They describe what each study did, not guidance of any kind.
No study designs indexed yet.
Identification and structure
Selank is a synthetic heptapeptide comprising the tuftsin fragment Thr-Lys-Pro-Arg with a C-terminal Pro-Gly-Pro extension added for enzymatic stability. It is supplied as a lyophilised powder. Identity is confirmed by mass spectrometry against the calculated mass and purity by reversed-phase HPLC with a stated method. Basic residues in the sequence affect chromatographic behaviour, so the specific method and gradient reported on the certificate of analysis matter when comparing purity figures between suppliers. Values on this record come from supplier documentation.
Discovery and characterisation history
Selank was developed by the same Russian research programme that produced Semax, based on the immunomodulatory peptide tuftsin, and is registered as a medicine in Russia for anxiety-related indications. As with Semax, that registration reflects a different regulatory tradition and evidentiary threshold from FDA or EMA review, and most supporting studies were published in Russian-language journals.
Mechanisms examined in published work
Published work examines effects on GABAergic and serotonergic signalling in rodent brain, modulation of enkephalin-degrading enzyme activity and consequent effects on endogenous enkephalin levels, changes in expression of genes related to inflammation and neurotransmission in rodent tissue, and behavioural endpoints in anxiety and learning models. Immunomodulatory activity inherited from the tuftsin motif, including effects on cytokine expression, is also examined.
Where the evidence is strong
Enzymatic stabilisation conferred by the Pro-Gly-Pro extension relative to bare tuftsin is documented. Effects on enkephalin degradation in rodent tissue have been reported in more than one study. Anxiolytic-type behavioural findings in standard rodent paradigms are reasonably consistent within the published set, and the absence of the sedative and motor effects characteristic of benzodiazepines in those same paradigms is a repeated observation.
Where the evidence is thin or absent
There are no randomised controlled trials meeting Western regulatory standards, and no approval outside the Russian registration. The human studies are small, frequently open-label or with incompletely described blinding, and conducted by groups connected to the original programme; independent replication is essentially absent. Rodent behavioural paradigms for anxiety have well-documented translational limitations that the literature rarely addresses. Human pharmacokinetics, including central exposure after peripheral administration, are poorly characterised. Long-term exposure data do not exist. The evidence base is thin, and this record is deliberately shorter than a padded version would be.
Handling, stability and storage
Store the lyophilised solid per the storage conditions on this record, protected from light and moisture, equilibrating the sealed vial before opening. Hygroscopic uptake and repeated freeze-thaw of reconstituted material are the principal analytical risks. This section covers laboratory handling of the material as supplied only, and contains no preparation or administration procedure.
Referenced literature
Indexed citations with verified PMIDs appear below. Analytical methods are described in testing methodology; documentation requirements in sourcing standards. Related records: Semax and the compound index.
Handling and storage
Handling conditions pending supplier documentation.
Published research
Evidence snapshot
No records indexed — no distribution to plot.
No literature is indexed for this compound on this site yet. Absence here is not evidence about the compound; it means nothing has been reviewed and published to this record.
This compound is supplied with per-lot certificates of analysis.
View supplier listing: SelankHow to read this
These entries index what has been published, not what has been established. Findings in cell culture or animal models do not transfer to human outcomes, and a citation appearing here is not a claim that the compound does anything in a person. None of these materials are approved for human or veterinary use. Summaries describe what each publication reported; read the source before relying on any of it.
Common questions
What is the recorded identity of Selank?
The reference record lists CAS number 129954-34-3, molecular formula C33H57N11O9, molar mass 751.88 g/mol. Identity is confirmed per batch by HPLC retention-time match and mass spectrometry on the certificate of analysis.
Is Selank intended for human or veterinary use?
No. Selank as catalogued here is a laboratory research material only. It is not a drug, food, or dietary supplement, and it is not for diagnostic or therapeutic use.
Related compounds
Semax
Research reference — 80714-61-0
Pinealon
Research reference — Cognitive
BPC-157
Research reference — 137525-51-0
TB-500
Research reference — Repair & recovery
GHK-Cu
Research reference — 89030-95-5
KPV
Research reference — 67727-97-3
This material is catalogued by our supply partner as a research-use-only item. Batch documentation is issued with each shipment.
Peptide calculator · Testing methodology · Sourcing standards · Compound index
Research use only
For laboratory research use only. Not for human or veterinary consumption. Not a drug, food, or dietary supplement. Not for diagnostic or therapeutic use. All materials referenced on this site are supplied to qualified laboratories and research institutions for in-vitro and analytical work.
